ROSSARI vs STYRENIX: Stock Comparison
STYRENIX PERFORMANCE is the larger company by market capitalisation. ROSSARI BIOTECH shows faster revenue growth, lower leverage and a higher net margin, while STYRENIX PERFORMANCE shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ROSSARI leads 8; STYRENIX leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ROSSARI | STYRENIX |
|---|---|---|
| Sector | Chemicals | Chemicals |
| Industry | Specialty Chemicals | Specialty Chemicals |
Price
| Metric | ROSSARI | STYRENIX |
|---|---|---|
| Live Price | ₹407.6 | ₹1,811.8 |
| Day Change | -0.2% | 0.54% |
| Volume | 49,434 | 71,489 |
| 52-Week High | ₹656.05 | ₹2,653 |
| 52-Week Low | ₹375 | ₹1,720 |
| Distance from 52W High | -37.87% | -31.71% |
Valuation
| Metric | ROSSARI | STYRENIX |
|---|---|---|
| Market Cap | ₹2,255 Cr | ₹3,151 Cr |
| P/E Ratio | 14.76x | 12.54x |
| P/B Ratio | 1.6x | 2.12x |
| EPS | ₹7.02 | ₹78.64 |
| Book Value | ₹240.7 | ₹776.95 |
| Dividend Yield | 0.12% | 2.58% |
Growth
| Metric | ROSSARI | STYRENIX |
|---|---|---|
| Revenue Growth (TTM YoY) | 18.2% | -12.1% |
| EPS Growth (TTM YoY) | 33.5% | 30.9% |
| Qtr Sales Growth | 0.05% | 0% |
| Qtr Profit Growth | 10.86% | 0% |
Profitability & Leverage
| Metric | ROSSARI | STYRENIX |
|---|---|---|
| ROE | 11.72% | 13.38% |
| ROCE | 11.79% | 12.38% |
| Net Margin | 6.14% | 5.42% |
| Operating Margin | 11.67% | 7.06% |
| Debt to Equity | 0.1x | 0.23x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | ROSSARI | STYRENIX |
|---|---|---|
| Promoter Holding | 63.63% | 46.24% |
| FII Holding | 1.84%▼ 0.18 pp | 1.31%▲ 0.45 pp |
| DII Holding | 14.19%▼ 0.45 pp | 14.44%▼ 3 pp |
| Public Holding | 15.83%▲ 0.63 pp | 38.01%▲ 2.55 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ROSSARI BIOTECH and STYRENIX PERFORMANCE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.